|
KMID : 0602820040100020035
|
|
Korean Journal of Bronchoesophagology
2004 Volume.10 No. 2 p.35 ~ p.42
|
|
|
Clinical Study for Efficacy and Safety of Rabeprazole Sodium(Pariet) in the Treatment of Laryngopharyngeal Reflex(LPR) Disease
|
|
Jung Kwang-Yoon
Kim Young-Mo
Sung Myung-Whun
Song Si-Youn
Kim Sung-Wan
Jin Sung-Min
Nam Soon-Yuhl
Kim Hyung-Tae
Choi Eun-Chang
Lee Dong-Wook
Kwon Soon-Young
Kim Dong-Young
Son Young-Ik
Chung Sung-Min
Kim Young-Ho
Lee Heung-Man
Kwon Joong-Keun
Jeon Byung-Seon
Kwon Ki-Whan
Kim Sang-Chul
Kim Yun-Hwan
Kim Jang-Moog
Kim Jung-Soo
Kim Chul-Ho
Moon Ji-Ho
Park Byung-Cheol
Bang Choong-Ill
Baek Byoung-Joon
An Chul-Min
Yang Yun-Su
Youn Sung-Moon
Lee Kun-Soo
Lee Kwang-Hyun
Lee Min-Ho
Jung Dae-Gun
Choi Tae-Wook
Hong Ki-Hwan
Hong Hyung-Jeong
|
|
|
Abstract
|
|
|
b>Background and objective : Rabeprazole is a new generation proton pump inhibitor, which has a rapid onset after first dose, predictable efficacy in all patients regardless of CYP2C19 genotype status, and less nocturnal acid breakthrough. The aim of the study is to investigate clinical efficacy and safety of rabeprazole sodium (Pariet 10mg qd)when administered once daily to patients with laryngopharyngeal reflux(LPR) disease.
Methods : Among the patients who had visited the Department of Otolaryngology, those with LPR symptoms, had undergone laryngoscopy. Symptoms and endoscopic laryngeal sings were recorded initially, at 1 month, 2 months, 3 months, and more than 3 months, All patients were evaluated for clinical efficacy on the basis of symptom scores, reflux finding score(RFS), and side effects.
Results : In general, most symptom scores and RFS improved over the time. Efficacy of the Pariet on LPR-related symptoms were 63.2%,77.5%,78.7%,and 90.9%before 4 weeks, 4 to 8 weeks, 8 to 12 weeks, and after 12 weeks respectively. Efficacy on the RFS were 61.8%,78.4%,82.9%,and 85.5% before 4 weeks, 4 to 8 weeks, 8 to 12 weeks, and after 12 weeks respectively. Pariet was well tolerated and was associated with few drug-related side effects.
Conclusion Because of its efficacy and safety, Pariet may prove to be an alternative to currently available proton pump inhibitors.
|
|
|
KEYWORD
|
|
|
Laryngopharyngeal reflux(LPR), Rabeprazole, PPI
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|